Stephanie Baker Bloomberg
- All
- News
-
Broke Russian Billionaire, Hit By War Sanctions, Says No Sway Over Putin
Mikhail Fridman was worth about $14 billion before the war. He's now worth about $10 billion on paper and is in the strange position of being an oligarch with essentially no cash.
-
When Will Covid Pandemic Really End? What Covax Says
On Jan. 23, 2020, the day the novel coronavirus forced the Chinese city of Wuhan into lockdown, two American doctors named Seth Berkley and Richard Hatchett met at the bar of the Hard Rock Hotel in Davos, Switzerland, to talk about vaccines.
-
AstraZeneca Moves From Favored Child To Problem Child Among Vaccines
Mene Pangalos, head of biopharmaceuticals research for AstraZeneca Plc, went to bed on Monday, March 22, feeling good for the first time in a while.
-
Oxford Vaccine Better At Stopping Covid Than Slowing Spread: Report
A vaccine from the University of Oxford and AstraZeneca Plc shows only a limited ability to stop transmission of the coronavirus despite preventing Covid-19 illness in a majority of those who are infected.
-
Oxford Vaccine Effective But Questions On Those Above 55: Report
On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.
-
Opinion: There Will Be A Price To Pay For Making Vaccines Too Expensive
The world is unequal enough and the Covid-19 pandemic threatens to make things more unequal still. Poorer countries have had to take on debt they will struggle to pay back. Their more fragile healthcare systems and crowded cities forced them into stricter and more economically harmful lockdowns, and poverty rates have risen dramatically. Now, they ...
-
Oxford Vaccine Shot That Works Better In Smaller Doses Raises Questions
The news reached Sarah Gilbert Saturday evening that the Covid-19 vaccine she's developed with AstraZeneca Plc appeared to work. But the University of Oxford professor had expected a key number: Was it more than 90% effective, as others have been -- or less?
-
Cambridge Analytica Won't Be Revived Under New Company Name
Cambridge Analytica announced last week that it was beginning bankruptcy proceedings, saying the media storm over its use of Facebook data had scared clients away.
-
Meet The Psychologist At The Center Of Facebook's Data Scandal
In a video published online in September, a social scientist named Alex Spectre made an earnest pitch for his new startup. Clad in the Silicon Valley uniform of open-collar shirt and blazer, Spectre boasted that his company -- Philometrics -- would revolutionize the way online surveys were done, making it easier for companies to design questionnair...
-
'Make Mumbai Great Again': Trump's Partner Says No Conflict Of Interest
As President Donald Trump prepares to host Indian Prime Minister Narendra Modi in Washington next week, his business partner in India is gearing up to sell high-priced condominiums at Trump Tower Mumbai.
-
Broke Russian Billionaire, Hit By War Sanctions, Says No Sway Over Putin
Mikhail Fridman was worth about $14 billion before the war. He's now worth about $10 billion on paper and is in the strange position of being an oligarch with essentially no cash.
-
When Will Covid Pandemic Really End? What Covax Says
On Jan. 23, 2020, the day the novel coronavirus forced the Chinese city of Wuhan into lockdown, two American doctors named Seth Berkley and Richard Hatchett met at the bar of the Hard Rock Hotel in Davos, Switzerland, to talk about vaccines.
-
AstraZeneca Moves From Favored Child To Problem Child Among Vaccines
Mene Pangalos, head of biopharmaceuticals research for AstraZeneca Plc, went to bed on Monday, March 22, feeling good for the first time in a while.
-
Oxford Vaccine Better At Stopping Covid Than Slowing Spread: Report
A vaccine from the University of Oxford and AstraZeneca Plc shows only a limited ability to stop transmission of the coronavirus despite preventing Covid-19 illness in a majority of those who are infected.
-
Oxford Vaccine Effective But Questions On Those Above 55: Report
On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.
-
Opinion: There Will Be A Price To Pay For Making Vaccines Too Expensive
The world is unequal enough and the Covid-19 pandemic threatens to make things more unequal still. Poorer countries have had to take on debt they will struggle to pay back. Their more fragile healthcare systems and crowded cities forced them into stricter and more economically harmful lockdowns, and poverty rates have risen dramatically. Now, they ...
-
Oxford Vaccine Shot That Works Better In Smaller Doses Raises Questions
The news reached Sarah Gilbert Saturday evening that the Covid-19 vaccine she's developed with AstraZeneca Plc appeared to work. But the University of Oxford professor had expected a key number: Was it more than 90% effective, as others have been -- or less?
-
Cambridge Analytica Won't Be Revived Under New Company Name
Cambridge Analytica announced last week that it was beginning bankruptcy proceedings, saying the media storm over its use of Facebook data had scared clients away.
-
Meet The Psychologist At The Center Of Facebook's Data Scandal
In a video published online in September, a social scientist named Alex Spectre made an earnest pitch for his new startup. Clad in the Silicon Valley uniform of open-collar shirt and blazer, Spectre boasted that his company -- Philometrics -- would revolutionize the way online surveys were done, making it easier for companies to design questionnair...
-
'Make Mumbai Great Again': Trump's Partner Says No Conflict Of Interest
As President Donald Trump prepares to host Indian Prime Minister Narendra Modi in Washington next week, his business partner in India is gearing up to sell high-priced condominiums at Trump Tower Mumbai.
